Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)

Inclusion Criteria: 1. Male or female 18 years of age or older 2. Diagnosis of at least two episodes of recurrent pericarditis\*, 3. At least 1 day with pericarditis pain ≥4 on the 11-point Numerical Rating Scale (NRS) within prior 7 days 4. One of; 1. C-Reactive Protein\*\* (CRP) level ≥1.0 mg/dL within prior 7 days OR 2. Evidence of pericardial inflammation assessed by delayed pericardial hyperenhancement on cardiac magnetic resonance imaging (CMR) 5. Currently receiving non-steroidal anti-inflammatory drugs (NSAIDs) and/or colchicine and/or corticosteroids (in any combination) for treatment of pericarditis in stable doses 6. Male patients with partners of childbearing potential who have had a vasectomy or are willing to use double barrier contraception methods during the conduct of the study and for 2 months after the last dose of study drug. 7. Women of childbearing potential willing to use an acceptable method of contraception starting with study drug administration and for a minimum of 2 months after study completion. Otherwise, women must be postmenopausal (at least 1 y absence of vaginal bleeding or spotting and confirmed by follicle stimulating hormone \[FSH\] ≥40 mIU/mL \[or ≥ 40 IU/L\] if less than 2 y postmenopausal) or be surgically sterile. * Diagnosis of pericarditis according to the 2015 European Society of Cardiology (ESC) Guidelines for the Diagnosis and Management of Pericardial Diseases (Adler et al. 2015): At least two of: 1. Pericarditic chest pain 2. Pericardial rub 3. New widespread ST-segment elevation or PR-segment depression according to electrocardiogram (ECG) findings 4. Pericardial effusion (new or worsening) * Conversion: 1 mg/dL CRP = 10 mg/L hs-CRP Exclusion Criteria: 1. Diagnosis of pericarditis that is secondary to specific prohibited etiologies, including tuberculosis (TB); neoplastic, purulent, or radiation etiologies; post-thoracic blunt trauma (e.g., motor vehicle accident); myocarditis 2. Estimated glomerular filtration rate (eGFR) \<30 mL/min at screening 3. Elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 5 times the upper limit of normal (ULN) or ALT or AST \>3x ULN plus bilirubin \>2x ULN 4. Sepsis, defined as documented bacteremia at the time of screening or other documented active infection 5. Prior history of sustained ventricular arrhythmia 6. History of QT interval prolongation 7. QTc interval \> 500 msec 8. Current participation in any research study involving investigational drugs or device 9. Inability or unwillingness to give informed consent 10. Ongoing drug or alcohol abuse 11. On any cannabinoid during the past month 12. Women who are pregnant or breastfeeding 13. Current diagnosis of cancer, with the exception of non-melanoma skin cancer 14. Any factor, which would make it unlikely that the patient can comply with the study procedures 15. Showing suicidal tendency as per the Columbia Suicide Severity Rating Scale (C-SSRS), administered at screening 16. On digoxin and/or type 1 or 3 antiarrhythmics 17. On immunosuppressive therapy with any of the following: 1. Rilonacept 2. Anakinra 3. Canakinumab 4. Methotrexate 5. Azathioprine 6. Cyclosporine 7. Intravenous immune globulin (IVIG)